SummaryWhen seriously ill patients run out of standard treatment options, they will often consider non-standard treatment options (such as treatments that are currently unapproved by the regulatory agency for the given indication). In general, an access program enables patient access to a non-reimbursed therapeutic agent, outside of a clinical trial setting. Compassionate access is typically for therapeutics that are not yet approved or TGA registered, and are still considered investigational. Compassionate access is an established process with increasing demands. This study is designed to provide a framework for which patients treated with compassionate access therapeutics can register, so that some of the limitations of ad hoc compassionate access programs can be overcome. A study committee will prospectively assess each individual patient's detailed treatment approach in an objective and time-efficient manner. If approved, the patient may be eligible to register into the treatment phase of the study.
All participants will have an individualised treatment plan. Possible treatments include targeted therapies.
This trial is treating patients with locally advanced, incurable or metastatic cancer.
Use the hyperlinks, where available to access additional clinical trial information.
Peter MacCallum Cancer Centre
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study